Benitec Biopharma Reports $11.8M Q2 Loss, $189M Cash; BB-301 Shows 24-Month Gains
Benitec Biopharma reported an $11.8 million net loss (−$0.26/share) and held $189 million in cash as of Dec 31, 2025. In its BB-301 gene therapy program, all four Cohort 1 patients met response criteria at 12 months and Patient 1 achieved deeper improvements at 24 months.
1. Second Quarter Financial Results
Benitec Biopharma reported $13.4 million in expenses for Q2 fiscal 2026, up from $10.8 million a year earlier, driven by $5.8 million in R&D and $7.5 million in G&A. The company posted an $11.8 million net loss (−$0.26 per share) and held $189 million in cash and cash equivalents as of Dec 31, 2025.
2. BB-301 Cohort 1 Responder Analysis
In the Phase 1b/2a BB-301 study, all four patients in Cohort 1 met predefined response criteria at the 12-month follow-up. Patient 1 completed the 24-month evaluation with deepening improvements in post-swallow pharyngeal residue and a reduced dysphagic symptom burden compared with the 12-month timepoint.
3. Cohort 2 Progress and Regulatory Plans
The first higher-dose patient in Cohort 2 was treated in the fourth quarter of 2025, with interim results expected in mid-2026. Benitec Biopharma plans a mid-year FDA meeting to finalize the pivotal BB-301 study design and has secured Fast Track and Orphan Drug designations for the therapy.